Thomas Meyer
Concepts (486)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Water | 29 | 2020 | 471 | 7.290 |
Why?
| | Ruthenium | 22 | 2020 | 34 | 5.270 |
Why?
| | Organometallic Compounds | 21 | 2014 | 115 | 4.410 |
Why?
| | Catalysis | 29 | 2020 | 322 | 2.740 |
Why?
| | Oxidation-Reduction | 41 | 2020 | 1091 | 2.580 |
Why?
| | Protons | 12 | 2016 | 96 | 2.460 |
Why?
| | Electron Transport | 16 | 2016 | 118 | 2.060 |
Why?
| | Titanium | 10 | 2013 | 85 | 2.010 |
Why?
| | Electrodes | 13 | 2020 | 116 | 1.730 |
Why?
| | Oxygen | 8 | 2020 | 998 | 1.440 |
Why?
| | Electrochemistry | 14 | 2017 | 74 | 1.430 |
Why?
| | Electron Transport Complex IV | 4 | 2016 | 61 | 1.330 |
Why?
| | Electrochemical Techniques | 7 | 2020 | 55 | 1.320 |
Why?
| | Alu Elements | 5 | 2025 | 28 | 1.260 |
Why?
| | Coordination Complexes | 6 | 2020 | 13 | 1.230 |
Why?
| | Electrons | 9 | 2013 | 88 | 1.200 |
Why?
| | Tin Compounds | 5 | 2020 | 17 | 1.160 |
Why?
| | Molecular Structure | 18 | 2014 | 505 | 1.150 |
Why?
| | Photochemical Processes | 6 | 2013 | 108 | 1.030 |
Why?
| | 2,2'-Dipyridyl | 3 | 2013 | 7 | 1.020 |
Why?
| | Models, Chemical | 6 | 2013 | 273 | 1.020 |
Why?
| | Hylobates | 3 | 2016 | 8 | 1.000 |
Why?
| | Solar Energy | 4 | 2013 | 34 | 0.990 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2024 | 101 | 0.840 |
Why?
| | Chlorides | 2 | 2015 | 137 | 0.830 |
Why?
| | Surface Properties | 10 | 2017 | 413 | 0.810 |
Why?
| | Copper | 2 | 2015 | 115 | 0.790 |
Why?
| | Benzoquinones | 2 | 2014 | 47 | 0.780 |
Why?
| | Amides | 2 | 2014 | 97 | 0.760 |
Why?
| | Pyridines | 5 | 2013 | 593 | 0.750 |
Why?
| | Oligopeptides | 3 | 2013 | 266 | 0.750 |
Why?
| | Long Interspersed Nucleotide Elements | 3 | 2022 | 32 | 0.750 |
Why?
| | Nanostructures | 3 | 2013 | 117 | 0.750 |
Why?
| | Coloring Agents | 3 | 2020 | 96 | 0.740 |
Why?
| | Peptides | 5 | 2014 | 976 | 0.680 |
Why?
| | Polymers | 2 | 2017 | 496 | 0.670 |
Why?
| | Ammonia | 2 | 2019 | 64 | 0.620 |
Why?
| | Metal Nanoparticles | 4 | 2015 | 85 | 0.610 |
Why?
| | Osmium | 2 | 2013 | 3 | 0.610 |
Why?
| | Nitrogen Cycle | 1 | 2019 | 11 | 0.600 |
Why?
| | Kinetics | 11 | 2014 | 1628 | 0.590 |
Why?
| | Papillomavirus Infections | 4 | 2025 | 369 | 0.580 |
Why?
| | Paracoccus denitrificans | 2 | 2015 | 3 | 0.560 |
Why?
| | Genome | 8 | 2018 | 309 | 0.550 |
Why?
| | Retroelements | 7 | 2025 | 52 | 0.550 |
Why?
| | Enzymes, Immobilized | 2 | 2015 | 29 | 0.540 |
Why?
| | Photochemistry | 5 | 2012 | 133 | 0.530 |
Why?
| | Gold | 3 | 2015 | 120 | 0.530 |
Why?
| | Photosynthesis | 4 | 2014 | 102 | 0.520 |
Why?
| | Light | 3 | 2020 | 401 | 0.510 |
Why?
| | Minisatellite Repeats | 1 | 2016 | 39 | 0.500 |
Why?
| | Phylogeny | 4 | 2014 | 1008 | 0.490 |
Why?
| | Hydroquinones | 2 | 2012 | 29 | 0.470 |
Why?
| | Thermus thermophilus | 2 | 2014 | 19 | 0.460 |
Why?
| | Hydrogen-Ion Concentration | 6 | 2015 | 556 | 0.440 |
Why?
| | Silver | 1 | 2015 | 38 | 0.440 |
Why?
| | Chlorine | 1 | 2015 | 64 | 0.440 |
Why?
| | Cytochrome b Group | 1 | 2014 | 22 | 0.430 |
Why?
| | Oxides | 2 | 2013 | 51 | 0.430 |
Why?
| | Proline | 3 | 2013 | 80 | 0.430 |
Why?
| | Ferric Compounds | 1 | 2014 | 55 | 0.410 |
Why?
| | NAD | 1 | 2014 | 78 | 0.410 |
Why?
| | Fluorine | 1 | 2013 | 17 | 0.400 |
Why?
| | Carbon Dioxide | 2 | 2012 | 242 | 0.400 |
Why?
| | Polystyrenes | 1 | 2013 | 38 | 0.400 |
Why?
| | Cobalt | 1 | 2013 | 51 | 0.390 |
Why?
| | Biofuels | 1 | 2012 | 15 | 0.380 |
Why?
| | Singlet Oxygen | 1 | 2012 | 18 | 0.380 |
Why?
| | Polymerization | 1 | 2013 | 128 | 0.380 |
Why?
| | Ruthenium Compounds | 2 | 2010 | 2 | 0.380 |
Why?
| | Benzyl Alcohol | 1 | 2012 | 12 | 0.370 |
Why?
| | Diphosphonates | 1 | 2012 | 70 | 0.370 |
Why?
| | Carbon Monoxide | 1 | 2012 | 83 | 0.360 |
Why?
| | Hydroxides | 1 | 2011 | 27 | 0.360 |
Why?
| | Cytochromes c1 | 1 | 2011 | 1 | 0.350 |
Why?
| | Cytochrome c Group | 1 | 2011 | 44 | 0.350 |
Why?
| | Papillomaviridae | 2 | 2019 | 121 | 0.340 |
Why?
| | Indium | 1 | 2010 | 8 | 0.330 |
Why?
| | Tin | 1 | 2010 | 9 | 0.320 |
Why?
| | Photosystem II Protein Complex | 2 | 2007 | 16 | 0.320 |
Why?
| | Photolysis | 1 | 2011 | 96 | 0.320 |
Why?
| | Tryptophan | 1 | 2011 | 181 | 0.320 |
Why?
| | Nitrogen | 2 | 2019 | 168 | 0.310 |
Why?
| | Nanoparticles | 3 | 2013 | 504 | 0.300 |
Why?
| | Models, Molecular | 7 | 2013 | 1622 | 0.290 |
Why?
| | Lung Neoplasms | 6 | 2024 | 2580 | 0.280 |
Why?
| | Recombination, Genetic | 4 | 2016 | 211 | 0.260 |
Why?
| | Signal Transduction | 4 | 2025 | 5214 | 0.250 |
Why?
| | Molecular Conformation | 5 | 2013 | 147 | 0.250 |
Why?
| | Human papillomavirus 16 | 1 | 2025 | 31 | 0.230 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2025 | 41 | 0.230 |
Why?
| | Myelin Proteins | 2 | 2016 | 45 | 0.230 |
Why?
| | Interleukin-7 | 1 | 2025 | 65 | 0.230 |
Why?
| | Deoxycytidine | 4 | 2014 | 203 | 0.220 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2025 | 49 | 0.220 |
Why?
| | Cottontail rabbit papillomavirus | 1 | 2024 | 3 | 0.220 |
Why?
| | ras Proteins | 1 | 2025 | 146 | 0.220 |
Why?
| | Energy Transfer | 3 | 2013 | 49 | 0.210 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2024 | 23 | 0.210 |
Why?
| | Mood Disorders | 1 | 2025 | 139 | 0.210 |
Why?
| | Rhadinovirus | 1 | 2024 | 20 | 0.210 |
Why?
| | RNA, Transfer | 1 | 2025 | 143 | 0.210 |
Why?
| | Solvents | 1 | 2004 | 111 | 0.210 |
Why?
| | Animals | 24 | 2025 | 38010 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1827 | 0.200 |
Why?
| | Herpesvirus 8, Human | 1 | 2024 | 66 | 0.200 |
Why?
| | Gammaherpesvirinae | 1 | 2024 | 45 | 0.200 |
Why?
| | DNA Repair | 1 | 2025 | 250 | 0.200 |
Why?
| | Sarcoma, Kaposi | 1 | 2024 | 83 | 0.200 |
Why?
| | RNA, Long Noncoding | 1 | 2025 | 176 | 0.190 |
Why?
| | Amines | 1 | 2003 | 38 | 0.190 |
Why?
| | Neuroprotective Agents | 1 | 2024 | 142 | 0.190 |
Why?
| | Janus Kinases | 1 | 2023 | 23 | 0.190 |
Why?
| | Genome-Wide Association Study | 3 | 2021 | 1452 | 0.190 |
Why?
| | Evolution, Molecular | 6 | 2014 | 507 | 0.190 |
Why?
| | Herpesviridae Infections | 1 | 2024 | 148 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 100 | 0.190 |
Why?
| | Luminescence | 2 | 2012 | 38 | 0.180 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2025 | 272 | 0.180 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 134 | 0.180 |
Why?
| | Interferon Type I | 1 | 2023 | 141 | 0.180 |
Why?
| | Stress, Physiological | 1 | 2025 | 453 | 0.180 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 111 | 0.180 |
Why?
| | Withanolides | 1 | 2021 | 3 | 0.170 |
Why?
| | Spectrophotometry | 2 | 2012 | 60 | 0.170 |
Why?
| | Protein Biosynthesis | 2 | 2025 | 453 | 0.170 |
Why?
| | Poly I-C | 1 | 2021 | 59 | 0.170 |
Why?
| | Lasers | 2 | 2012 | 131 | 0.170 |
Why?
| | Mutation | 4 | 2021 | 4053 | 0.170 |
Why?
| | Thermodynamics | 4 | 2007 | 424 | 0.170 |
Why?
| | Hydrogen Bonding | 3 | 2016 | 169 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2004 | 252 | 0.170 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2021 | 84 | 0.170 |
Why?
| | Quantum Theory | 2 | 2011 | 93 | 0.160 |
Why?
| | DNA Transposable Elements | 2 | 2014 | 121 | 0.160 |
Why?
| | Edetic Acid | 1 | 2020 | 48 | 0.160 |
Why?
| | Biomimetics | 1 | 2020 | 43 | 0.160 |
Why?
| | Sodium Nitrite | 1 | 2020 | 39 | 0.160 |
Why?
| | Skin Neoplasms | 2 | 2024 | 869 | 0.160 |
Why?
| | Circular Dichroism | 2 | 2013 | 148 | 0.150 |
Why?
| | HMGN1 Protein | 1 | 2018 | 1 | 0.150 |
Why?
| | Mitochondria, Heart | 1 | 2019 | 103 | 0.150 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 1133 | 0.150 |
Why?
| | Immunotherapy | 2 | 2021 | 659 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 647 | 0.140 |
Why?
| | alpha-Synuclein | 1 | 2019 | 44 | 0.140 |
Why?
| | Transcription Factors | 3 | 2022 | 1754 | 0.140 |
Why?
| | Molecular Sequence Data | 6 | 2014 | 2942 | 0.140 |
Why?
| | Blood | 1 | 2019 | 110 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 875 | 0.140 |
Why?
| | Humans | 37 | 2025 | 143560 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2014 | 441 | 0.140 |
Why?
| | Biological Products | 1 | 2021 | 246 | 0.130 |
Why?
| | Genetic Variation | 3 | 2014 | 1008 | 0.130 |
Why?
| | Imidazoles | 1 | 2018 | 252 | 0.130 |
Why?
| | Buffers | 1 | 2017 | 56 | 0.130 |
Why?
| | Cytoskeletal Proteins | 2 | 2016 | 154 | 0.130 |
Why?
| | Crystallography, X-Ray | 2 | 2013 | 488 | 0.130 |
Why?
| | Pseudomonas stutzeri | 1 | 2016 | 2 | 0.130 |
Why?
| | Cholesterol | 2 | 2021 | 404 | 0.130 |
Why?
| | Rhodobacter sphaeroides | 1 | 2016 | 7 | 0.130 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 651 | 0.130 |
Why?
| | Vibrio cholerae | 1 | 2016 | 15 | 0.130 |
Why?
| | Mice | 11 | 2025 | 18378 | 0.120 |
Why?
| | Proteins | 2 | 2016 | 1022 | 0.120 |
Why?
| | Munc18 Proteins | 1 | 2016 | 24 | 0.120 |
Why?
| | Genome, Human | 3 | 2025 | 429 | 0.120 |
Why?
| | Electric Power Supplies | 2 | 2013 | 51 | 0.120 |
Why?
| | Neurons | 2 | 2022 | 1636 | 0.120 |
Why?
| | Phenothiazines | 2 | 2006 | 8 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 586 | 0.110 |
Why?
| | Silver Compounds | 1 | 2015 | 5 | 0.110 |
Why?
| | Potentiometry | 2 | 2016 | 4 | 0.110 |
Why?
| | Cerium | 1 | 2015 | 18 | 0.110 |
Why?
| | Chemical Precipitation | 1 | 2015 | 39 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2018 | 502 | 0.110 |
Why?
| | Carbonates | 1 | 2015 | 11 | 0.110 |
Why?
| | HeLa Cells | 1 | 2016 | 650 | 0.110 |
Why?
| | Karyotype | 1 | 2014 | 17 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2014 | 44 | 0.110 |
Why?
| | Solutions | 1 | 2015 | 168 | 0.110 |
Why?
| | Time Factors | 4 | 2013 | 7032 | 0.110 |
Why?
| | Macaca mulatta | 2 | 2022 | 191 | 0.110 |
Why?
| | Pan troglodytes | 3 | 2008 | 66 | 0.110 |
Why?
| | Fluorouracil | 3 | 2010 | 210 | 0.100 |
Why?
| | Ions | 1 | 2013 | 67 | 0.100 |
Why?
| | Enzyme Activation | 1 | 2015 | 790 | 0.100 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 686 | 0.100 |
Why?
| | Survival Analysis | 5 | 2014 | 1332 | 0.100 |
Why?
| | Bacteria | 1 | 2020 | 888 | 0.100 |
Why?
| | Brain | 2 | 2022 | 2892 | 0.100 |
Why?
| | Particle Size | 2 | 2011 | 406 | 0.100 |
Why?
| | Phosphoric Acids | 1 | 2012 | 16 | 0.100 |
Why?
| | Strepsirhini | 1 | 2012 | 2 | 0.100 |
Why?
| | Tantalum | 1 | 2012 | 3 | 0.100 |
Why?
| | Lipid Bilayers | 1 | 2013 | 103 | 0.100 |
Why?
| | Anthracenes | 1 | 2012 | 32 | 0.090 |
Why?
| | Asia, Southeastern | 1 | 2012 | 12 | 0.090 |
Why?
| | Acrylates | 1 | 2012 | 48 | 0.090 |
Why?
| | Pancreatic Neoplasms | 2 | 2014 | 924 | 0.090 |
Why?
| | Mutagenesis, Insertional | 1 | 2012 | 67 | 0.090 |
Why?
| | Luminescent Agents | 1 | 2012 | 8 | 0.090 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 178 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 6043 | 0.090 |
Why?
| | Iridium | 1 | 2011 | 7 | 0.090 |
Why?
| | Quartz Crystal Microbalance Techniques | 1 | 2011 | 7 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2014 | 267 | 0.090 |
Why?
| | Zinc | 1 | 2015 | 300 | 0.090 |
Why?
| | Semiconductors | 1 | 2011 | 40 | 0.090 |
Why?
| | Geography | 1 | 2012 | 202 | 0.090 |
Why?
| | Selenium Compounds | 1 | 2011 | 21 | 0.090 |
Why?
| | Molecular Dynamics Simulation | 1 | 2013 | 257 | 0.090 |
Why?
| | Biology | 1 | 2012 | 92 | 0.090 |
Why?
| | Data Mining | 1 | 2012 | 118 | 0.090 |
Why?
| | Cadmium Compounds | 1 | 2011 | 33 | 0.090 |
Why?
| | Glutamates | 1 | 2011 | 62 | 0.080 |
Why?
| | Ligands | 3 | 2016 | 670 | 0.080 |
Why?
| | Prevalence | 4 | 2022 | 2830 | 0.080 |
Why?
| | Genetic Loci | 1 | 2012 | 279 | 0.080 |
Why?
| | Rabbits | 2 | 2024 | 665 | 0.080 |
Why?
| | DNA-Binding Proteins | 3 | 2025 | 1524 | 0.080 |
Why?
| | Guanine | 1 | 2011 | 81 | 0.080 |
Why?
| | Cytokines | 1 | 2018 | 2097 | 0.080 |
Why?
| | Carboplatin | 1 | 2011 | 145 | 0.080 |
Why?
| | Mice, Nude | 3 | 2021 | 710 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2014 | 1095 | 0.080 |
Why?
| | Female | 18 | 2025 | 77252 | 0.080 |
Why?
| | Organoplatinum Compounds | 1 | 2010 | 51 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2025 | 3109 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 623 | 0.080 |
Why?
| | Leucovorin | 1 | 2010 | 87 | 0.080 |
Why?
| | Dimerization | 1 | 2010 | 197 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2016 | 944 | 0.080 |
Why?
| | Phosphorylation | 3 | 2025 | 1781 | 0.080 |
Why?
| | DNA, Viral | 2 | 2019 | 366 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 677 | 0.080 |
Why?
| | Aged | 11 | 2024 | 25322 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1906 | 0.070 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2008 | 5 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1062 | 0.070 |
Why?
| | Chromosome Inversion | 1 | 2008 | 19 | 0.070 |
Why?
| | Metals | 1 | 2010 | 142 | 0.070 |
Why?
| | Chromosomes | 1 | 2008 | 107 | 0.070 |
Why?
| | Stereoisomerism | 2 | 2011 | 103 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3611 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 686 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 927 | 0.070 |
Why?
| | Radiotherapy, Conformal | 2 | 2006 | 73 | 0.070 |
Why?
| | Membranes | 1 | 2007 | 13 | 0.070 |
Why?
| | Hydrogen | 1 | 2008 | 75 | 0.070 |
Why?
| | Middle Aged | 11 | 2024 | 35343 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2417 | 0.070 |
Why?
| | Cercopithecidae | 1 | 2007 | 8 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 642 | 0.070 |
Why?
| | Enzymes | 1 | 2007 | 65 | 0.070 |
Why?
| | Male | 15 | 2024 | 71501 | 0.060 |
Why?
| | Pyrazoles | 1 | 2011 | 496 | 0.060 |
Why?
| | Down-Regulation | 2 | 2020 | 644 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1474 | 0.060 |
Why?
| | Temperature | 1 | 2010 | 676 | 0.060 |
Why?
| | Bronchogenic Cyst | 1 | 2006 | 8 | 0.060 |
Why?
| | Barotrauma | 1 | 2006 | 4 | 0.060 |
Why?
| | Explosions | 1 | 2006 | 15 | 0.060 |
Why?
| | Aircraft | 1 | 2006 | 23 | 0.060 |
Why?
| | Luminescent Measurements | 2 | 2003 | 76 | 0.060 |
Why?
| | Embolism, Air | 1 | 2006 | 14 | 0.060 |
Why?
| | Database Management Systems | 1 | 2006 | 51 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2131 | 0.060 |
Why?
| | Intracranial Embolism | 1 | 2006 | 34 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2010 | 586 | 0.060 |
Why?
| | Tetrazoles | 1 | 2006 | 45 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2195 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 773 | 0.060 |
Why?
| | Tyrosine | 1 | 2006 | 229 | 0.060 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2016 | 85 | 0.060 |
Why?
| | Treatment Outcome | 5 | 2024 | 11365 | 0.060 |
Why?
| | Acetyltransferases | 1 | 2025 | 21 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2025 | 4182 | 0.060 |
Why?
| | Databases, Genetic | 1 | 2006 | 248 | 0.060 |
Why?
| | Gene Knockout Techniques | 1 | 2025 | 117 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2007 | 330 | 0.060 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2004 | 20 | 0.060 |
Why?
| | Gene Library | 1 | 2025 | 123 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 2020 | 0.050 |
Why?
| | Isotopes | 1 | 2004 | 34 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2020 | 4522 | 0.050 |
Why?
| | Hydroxylamines | 1 | 2024 | 8 | 0.050 |
Why?
| | Anthraquinones | 1 | 2004 | 12 | 0.050 |
Why?
| | Oxadiazoles | 1 | 2024 | 36 | 0.050 |
Why?
| | Acetylation | 1 | 2025 | 249 | 0.050 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 2 | 2016 | 88 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2004 | 108 | 0.050 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2024 | 45 | 0.050 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2024 | 34 | 0.050 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 576 | 0.050 |
Why?
| | Indicators and Reagents | 1 | 2003 | 109 | 0.050 |
Why?
| | Iron | 1 | 2006 | 345 | 0.050 |
Why?
| | Ribosomes | 1 | 2025 | 190 | 0.050 |
Why?
| | Nerve Tissue Proteins | 1 | 2007 | 607 | 0.050 |
Why?
| | Haplotypes | 1 | 2025 | 496 | 0.050 |
Why?
| | Phthalazines | 1 | 2024 | 63 | 0.050 |
Why?
| | Liver Neoplasms | 1 | 2010 | 758 | 0.050 |
Why?
| | Virus Latency | 1 | 2024 | 80 | 0.050 |
Why?
| | Bile Duct Neoplasms | 1 | 2004 | 121 | 0.050 |
Why?
| | Purines | 1 | 2004 | 185 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2004 | 368 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2056 | 0.050 |
Why?
| | Topotecan | 1 | 2003 | 14 | 0.050 |
Why?
| | Phenazines | 1 | 2002 | 13 | 0.050 |
Why?
| | Nitrogen Isotopes | 1 | 2003 | 72 | 0.050 |
Why?
| | Feasibility Studies | 2 | 2022 | 1051 | 0.050 |
Why?
| | STAT Transcription Factors | 1 | 2023 | 24 | 0.050 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2023 | 35 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2003 | 98 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 169 | 0.050 |
Why?
| | Genome, Viral | 1 | 2024 | 224 | 0.050 |
Why?
| | Biodiversity | 1 | 2006 | 421 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 234 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2003 | 205 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 162 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2856 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1272 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2024 | 211 | 0.050 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2006 | 308 | 0.050 |
Why?
| | Chromosomal Instability | 1 | 2021 | 21 | 0.040 |
Why?
| | Nucleic Acid Conformation | 1 | 2025 | 728 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2023 | 197 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 54 | 0.040 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 833 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 423 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 941 | 0.040 |
Why?
| | Endosomes | 1 | 2023 | 144 | 0.040 |
Why?
| | Fallopian Tubes | 1 | 2021 | 33 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2025 | 523 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2519 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 549 | 0.040 |
Why?
| | Interferon Inducers | 1 | 2021 | 8 | 0.040 |
Why?
| | Gene Transfer, Horizontal | 2 | 2014 | 35 | 0.040 |
Why?
| | Glutamine | 1 | 2021 | 109 | 0.040 |
Why?
| | Adult | 7 | 2024 | 40012 | 0.040 |
Why?
| | Piperazines | 1 | 2024 | 393 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 444 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2021 | 160 | 0.040 |
Why?
| | Europe | 1 | 2022 | 410 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2004 | 617 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 704 | 0.040 |
Why?
| | Stents | 1 | 2004 | 543 | 0.040 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1252 | 0.040 |
Why?
| | Germany | 2 | 2014 | 139 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2011 | 8072 | 0.040 |
Why?
| | Apelin | 1 | 2019 | 10 | 0.040 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 16 | 0.040 |
Why?
| | Histones | 1 | 2025 | 666 | 0.040 |
Why?
| | Nitrites | 1 | 2020 | 88 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1263 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2019 | 55 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 196 | 0.040 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 143 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 368 | 0.040 |
Why?
| | Neoadjuvant Therapy | 2 | 2014 | 438 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2621 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 2017 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 974 | 0.040 |
Why?
| | Nuclear Localization Signals | 1 | 2019 | 18 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2003 | 320 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 186 | 0.040 |
Why?
| | Synteny | 1 | 2018 | 14 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 195 | 0.040 |
Why?
| | Carcinoma, Renal Cell | 1 | 2021 | 225 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2011 | 280 | 0.030 |
Why?
| | Th1 Cells | 1 | 2018 | 140 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1058 | 0.030 |
Why?
| | Genomics | 2 | 2018 | 831 | 0.030 |
Why?
| | Drug Synergism | 1 | 2018 | 370 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1511 | 0.030 |
Why?
| | CpG Islands | 1 | 2018 | 166 | 0.030 |
Why?
| | Epigenomics | 1 | 2018 | 115 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 539 | 0.030 |
Why?
| | Biofilms | 1 | 2020 | 278 | 0.030 |
Why?
| | Mitochondria | 1 | 2024 | 988 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2020 | 361 | 0.030 |
Why?
| | Cytochrome-c Peroxidase | 1 | 2016 | 1 | 0.030 |
Why?
| | Risk Factors | 3 | 2021 | 10644 | 0.030 |
Why?
| | Echocardiography | 1 | 2019 | 652 | 0.030 |
Why?
| | Kidney Neoplasms | 1 | 2021 | 407 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2019 | 718 | 0.030 |
Why?
| | Gene Deletion | 2 | 2008 | 394 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 86 | 0.030 |
Why?
| | Heme | 1 | 2016 | 84 | 0.030 |
Why?
| | Oxidoreductases | 1 | 2016 | 95 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1465 | 0.030 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 626 | 0.030 |
Why?
| | Membrane Potentials | 1 | 2016 | 280 | 0.030 |
Why?
| | Monocytes | 1 | 2018 | 545 | 0.030 |
Why?
| | Survival Rate | 2 | 2014 | 2003 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 612 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1369 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2021 | 1125 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 546 | 0.030 |
Why?
| | Switzerland | 1 | 2014 | 43 | 0.030 |
Why?
| | Solid-Phase Synthesis Techniques | 1 | 2014 | 11 | 0.030 |
Why?
| | Cohort Studies | 2 | 2016 | 5891 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2014 | 10 | 0.030 |
Why?
| | Base Sequence | 2 | 2008 | 2199 | 0.030 |
Why?
| | Transcription Termination, Genetic | 1 | 2014 | 21 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2019 | 793 | 0.030 |
Why?
| | 1,2-Dipalmitoylphosphatidylcholine | 1 | 2013 | 9 | 0.030 |
Why?
| | Chromatin | 1 | 2018 | 554 | 0.030 |
Why?
| | Hominidae | 1 | 2014 | 87 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1505 | 0.030 |
Why?
| | Age Distribution | 1 | 2014 | 398 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 383 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2014 | 173 | 0.030 |
Why?
| | Protein Conformation | 1 | 2016 | 942 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2021 | 2542 | 0.020 |
Why?
| | Lung Diseases | 1 | 2020 | 787 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 1029 | 0.020 |
Why?
| | Cell Line | 1 | 2019 | 2897 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 131 | 0.020 |
Why?
| | Colloids | 1 | 2013 | 61 | 0.020 |
Why?
| | Dielectric Spectroscopy | 1 | 2012 | 1 | 0.020 |
Why?
| | Madagascar | 1 | 2012 | 45 | 0.020 |
Why?
| | Click Chemistry | 1 | 2013 | 50 | 0.020 |
Why?
| | Cisplatin | 1 | 2014 | 333 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 576 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2014 | 266 | 0.020 |
Why?
| | Bayes Theorem | 1 | 2014 | 426 | 0.020 |
Why?
| | Prospective Studies | 3 | 2014 | 7900 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2019 | 2852 | 0.020 |
Why?
| | Coumarins | 1 | 2011 | 17 | 0.020 |
Why?
| | Nitrophenols | 1 | 2011 | 32 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 347 | 0.020 |
Why?
| | Pemetrexed | 1 | 2011 | 33 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 92 | 0.020 |
Why?
| | Biphenyl Compounds | 1 | 2011 | 70 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2261 | 0.020 |
Why?
| | Cell Membrane | 1 | 2013 | 708 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2010 | 26 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5610 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1736 | 0.020 |
Why?
| | 3' Flanking Region | 1 | 2008 | 7 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1877 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 157 | 0.020 |
Why?
| | Adenocarcinoma | 2 | 2007 | 911 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3625 | 0.020 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2007 | 29 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 577 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 921 | 0.020 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2007 | 117 | 0.020 |
Why?
| | Software Design | 1 | 2006 | 25 | 0.020 |
Why?
| | Endogenous Retroviruses | 1 | 2007 | 39 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2177 | 0.020 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2006 | 52 | 0.020 |
Why?
| | Exons | 1 | 2007 | 359 | 0.020 |
Why?
| | Cations | 1 | 2006 | 83 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2006 | 114 | 0.010 |
Why?
| | Precancerous Conditions | 1 | 2007 | 165 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 96 | 0.010 |
Why?
| | Alleles | 1 | 2008 | 893 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 313 | 0.010 |
Why?
| | Cell Lineage | 1 | 2007 | 368 | 0.010 |
Why?
| | Patient Compliance | 1 | 2010 | 617 | 0.010 |
Why?
| | Colonic Neoplasms | 1 | 2007 | 259 | 0.010 |
Why?
| | BALB 3T3 Cells | 1 | 2004 | 1 | 0.010 |
Why?
| | Biological Evolution | 1 | 2008 | 493 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 377 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 823 | 0.010 |
Why?
| | Neoplasms | 1 | 2018 | 2804 | 0.010 |
Why?
| | DNA Probes | 1 | 2002 | 59 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4241 | 0.010 |
Why?
| | Cell Division | 1 | 2004 | 806 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2194 | 0.010 |
Why?
| | Software | 1 | 2007 | 687 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1504 | 0.010 |
Why?
| | Child | 1 | 2022 | 22725 | 0.010 |
Why?
| | Internet | 1 | 2006 | 698 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 839 | 0.010 |
Why?
| | Age Factors | 1 | 2007 | 3328 | 0.010 |
Why?
| | Models, Biological | 1 | 2007 | 1831 | 0.010 |
Why?
| | Algorithms | 1 | 2006 | 1813 | 0.010 |
Why?
| | Palliative Care | 1 | 2004 | 852 | 0.010 |
Why?
| | Retrospective Studies | 2 | 2006 | 16740 | 0.010 |
Why?
| | Prognosis | 1 | 2004 | 4152 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2006 | 2779 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3577 | 0.010 |
Why?
|
|
Meyer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|